$CUE
Cue Biopharma Inc

2019 Q2 Form 10-Q Financial Statement

#000156459019017298 Filed on May 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $1.055M $370.0K $190.0K
YoY Change 513.37% 94.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.390M $3.430M $1.700M
YoY Change 52.7% 101.76% 91.01%
% of Gross Profit
Research & Development $6.867M $8.353M $5.819M
YoY Change 26.84% 43.55% 136.45%
% of Gross Profit
Depreciation & Amortization $205.0K $205.0K $167.0K
YoY Change 5.13% 22.75% 149.25%
% of Gross Profit
Operating Expenses $10.29M $11.80M $7.522M
YoY Change 34.56% 56.83% 124.54%
Operating Profit -$11.43M -$7.522M
YoY Change 51.91% 124.54%
Interest Expense $96.00K $114.0K $0.00
YoY Change -43.53%
% of Operating Profit
Other Income/Expense, Net $122.0K $160.0K -$1.000K
YoY Change -29.07% -16100.0%
Pretax Income -$9.109M -$11.27M -$7.510M
YoY Change 24.78% 50.07% 124.18%
Income Tax $413.0K
% Of Pretax Income
Net Earnings -$9.522M -$11.27M -$7.523M
YoY Change 30.44% 49.77% 124.57%
Net Earnings / Revenue -902.56% -3045.14% -3959.47%
Basic Earnings Per Share
Diluted Earnings Per Share -$457.3K -$543.9K -$373.3K
COMMON SHARES
Basic Shares Outstanding 20.78M 20.73M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.26M $30.88M $53.20M
YoY Change -38.31% -41.96%
Cash & Equivalents $24.26M $21.91M $53.10M
Short-Term Investments $3.995M $8.966M $100.0K
Other Short-Term Assets $1.000M $1.000M $2.800M
YoY Change -71.43% -64.29%
Inventory
Prepaid Expenses
Receivables $522.0K
Other Receivables $0.00
Total Short-Term Assets $29.87M $31.97M $55.93M
YoY Change -39.35% -42.84%
LONG-TERM ASSETS
Property, Plant & Equipment $2.208M $2.595M $2.423M
YoY Change -20.09% 7.1%
Goodwill
YoY Change
Intangibles $175.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $838.0K $771.0K $800.0K
YoY Change -6.89% -3.63%
Total Long-Term Assets $11.89M $13.22M $3.397M
YoY Change 207.66% 289.17%
TOTAL ASSETS
Total Short-Term Assets $29.87M $31.97M $55.93M
Total Long-Term Assets $11.89M $13.22M $3.397M
Total Assets $41.76M $45.19M $59.33M
YoY Change -21.38% -23.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.289M $2.893M $1.200M
YoY Change 319.23% 141.08%
Accrued Expenses $2.580M $2.149M $300.0K
YoY Change 129.54% 616.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.27M $10.57M $4.100M
YoY Change 280.29% 157.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.20M $9.900M
YoY Change
Total Long-Term Liabilities $10.20M $9.900M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.27M $10.57M $4.100M
Total Long-Term Liabilities $10.20M $9.900M $0.00
Total Liabilities $21.48M $20.45M $4.084M
YoY Change 453.19% 400.73%
SHAREHOLDERS EQUITY
Retained Earnings -$92.59M -$83.07M -$40.34M
YoY Change 94.4% 105.9%
Common Stock $112.9M $107.8M
YoY Change 16.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.28M $24.74M $55.24M
YoY Change
Total Liabilities & Shareholders Equity $41.76M $45.19M $59.33M
YoY Change -21.38% -23.83%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$9.522M -$11.27M -$7.523M
YoY Change 30.44% 49.77% 124.57%
Depreciation, Depletion And Amortization $205.0K $205.0K $167.0K
YoY Change 5.13% 22.75% 149.25%
Cash From Operating Activities -$6.670M -$8.475M -$9.759M
YoY Change 3.25% -13.16% 182.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $19.00K $673.0K
YoY Change -100.0% -97.18% 21.04%
Acquisitions
YoY Change
Other Investing Activities $5.130M $9.500M
YoY Change
Cash From Investing Activities $5.130M $9.481M -$673.0K
YoY Change -775.0% -1508.77% 20.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.740M 257.0K
YoY Change
NET CHANGE
Cash From Operating Activities -6.670M -8.475M -9.759M
Cash From Investing Activities 5.130M 9.481M -673.0K
Cash From Financing Activities 3.740M 257.0K
Net Change In Cash 2.200M 1.263M -10.43M
YoY Change -130.47% -112.11% 159.5%
FREE CASH FLOW
Cash From Operating Activities -$6.670M -$8.475M -$9.759M
Capital Expenditures $0.00 $19.00K $673.0K
Free Cash Flow -$6.670M -$8.494M -$10.43M
YoY Change 17.02% -18.58% 159.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Trading Symbol
TradingSymbol
CUE
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001645460
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2595000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
31968000
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q4 us-gaap Liabilities
Liabilities
11391000
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20783246
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21913000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
18413000
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1039000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1347000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
40610000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8691000
CY2019Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1013000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1013000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
771000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
809000
CY2019Q1 us-gaap Assets
Assets
45188000
CY2018Q4 us-gaap Assets
Assets
45363000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2893000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2035000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2149000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1788000
CY2019Q1 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
1887000
CY2018Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2012000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
381000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3644000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10573000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6216000
CY2019Q1 cue Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
4930000
CY2018Q4 cue Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
5175000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4947000
CY2019Q1 us-gaap Liabilities
Liabilities
20450000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
21000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
107788000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
105763000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83068000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20800000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
8966000
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2781000
CY2019Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3444000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8353000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11427000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7522000
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
114000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7523000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71801000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
24738000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
33972000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45188000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45363000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
61607000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20783246
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20697453
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20783246
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20697453
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
370000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1703000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5819000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
11797000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
7522000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
46000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
160000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11267000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11270000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7523000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20718233
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20063609
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1158000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
55242000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-11267000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-7523000
CY2019Q1 us-gaap Depreciation
Depreciation
205000
CY2018Q1 us-gaap Depreciation
Depreciation
167000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1768000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1158000
CY2018Q1 cue Operating Lease Rent Payments
OperatingLeaseRentPayments
27000
CY2019Q1 cue Operating Lease Right Of Use Amortization
OperatingLeaseRightOfUseAmortization
1001000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
756000
CY2019Q1 cue Other Non Cash Charges
OtherNonCashCharges
-5000
CY2019Q1 cue Premium Paid On Securities Purchased
PremiumPaidOnSecuritiesPurchased
45000
CY2018Q1 cue Increase Decrease In Research And Development Contract Advances
IncreaseDecreaseInResearchAndDevelopmentContractAdvances
-531000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
225000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
481000
CY2018Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-1060000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
858000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-391000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
361000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-599000
CY2019Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-370000
CY2018Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-472000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8475000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9759000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
673000
CY2019Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-9500000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9481000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-673000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10432000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20850000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
257000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
257000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1263000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63534000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22113000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53102000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
227000
CY2019Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts previously reported in current liabilities for the prior period have been reclassified to the current period presentation to segregate accounts payable and accrued liabilities to conform with current period presentation.&nbsp;&nbsp;Also, certain amounts previously reported in research and development contract advances have been reclassified to the current period presentation to combine research and development contract advances and prepaid expenses.&nbsp;&nbsp;In addition, certain amounts previously reported as reductions to research and development expenses have been reclassified to collaboration revenue to conform with current period presentation.&nbsp;&nbsp;There was no impact to reported net loss.&nbsp;&nbsp;The reclassifications did not have a material impact on previously reported financial statements.</p>
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</p>
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4166000
CY2019Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2019Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2019Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
30879000
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
150000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
150000
CY2019Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2019Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2018Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2018Q4 cue Leases Rent Liability
LeasesRentLiability
-381000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6467194
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4009662
CY2019Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21913385
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
8966250
CY2019Q1 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
28960000
CY2018Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
8969000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
18424000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18413000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4147000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1571000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1366000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0249
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0259
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.820
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.902
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4540321
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
774600
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
85793
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14375
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5214753
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1912524
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.33
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.03
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.62
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M3D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M17D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M10D
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16123087
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
398642
CY2019Q1 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
7.73
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1768000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1158000
CY2019Q1 cue Number Of Tranches
NumberOfTranches
2
CY2019Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2842000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4910000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1432000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9184000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
594000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8590000
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1137000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
670000

Files In Submission

Name View Source Status
0001564590-19-017298-index-headers.html Edgar Link pending
0001564590-19-017298-index.html Edgar Link pending
0001564590-19-017298.txt Edgar Link pending
0001564590-19-017298-xbrl.zip Edgar Link pending
cue-10q_20190331.htm Edgar Link pending
cue-20190331.xml Edgar Link completed
cue-20190331.xsd Edgar Link pending
cue-20190331_cal.xml Edgar Link unprocessable
cue-20190331_def.xml Edgar Link unprocessable
cue-20190331_lab.xml Edgar Link unprocessable
cue-20190331_pre.xml Edgar Link unprocessable
cue-ex311_7.htm Edgar Link pending
cue-ex312_8.htm Edgar Link pending
cue-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g55ls1dg0ogi000001.jpg Edgar Link pending
g55ls1dg0ogi000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending